Patent ID: 8119159

Claim:
A solid oral dosage form comprising a pharmaceutical composition consisting of: (a) a therapeutically effective amount of a bisphosphonate selected from the group consisting of alendronate, clodronate, etidronate, incadronate, ibandronate, minodronate, pamidronate, risedronate, tiludronate and zoledronate; (b) a therapeutically effective amount of one or more enhancers, each of which is a salt of a medium chain fatty acid having a carbon chain length of from 8 to 14 carbon atoms and is a solid at room temperature, wherein the one or more enhancers promote absorption of the bisphosphonate at the gastrointestinal tract cell lining; and (c) one or more excipients selected from the group consisting of rate-controlling polymeric materials, diluents, lubricants, disintegrants, plasticizers, anti-tack agents, opacifying agents, pigments, and flavorings.